Corrigendum to 'MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC' [Journal of Thoracic Oncology 19 Issue 3 (2024) 434-450]

Affiliations

• ¹ Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts.
• ² Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
• ³ Department of Biostatistics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.
• ⁴ Division of Bioinformatics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
• ⁵ Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
• ⁶ Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
• ⁷ Department of Surgery, Kindai University Hospital, Osaka-Sayama, Japan.
• ⁸ Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts. Electronic address: donald_kufe@dfci.harvard.edu.